FIG. 6.

Proposed model for therapeutics targeting mitochondrial dynamics. Impaired mitochondrial fission/fusion and mitophagy and the consequent accumulation of fragmented and dysfunctional mitochondria are common hallmarks of cardiac diseases. Pharmacological interventions that improve mitochondrial connectiveness and clearance such as P110, Mdivi-1, or SAMβA play a critical role in the maintenance of mitochondrial health, therefore becoming potential novel therapeutic targets for cardiac diseases. SAMβA, selective antagonist of Mfn1-βIIPKC association.